ATC Group: N05BB01 Hydroxyzine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N05BB01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N05 Psycholeptics
3 N05B Anxiolytics
4 N05BB Diphenylmethane derivatives
5 N05BB01 Hydroxyzine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 75 mg
PAREN - Parenteral 75 mg

Active ingredients in N05BB01

Active Ingredient Description
Hydroxyzine

Hydroxyzine is a first generation antihistamine, a piperazine derivative, with antimuscarinic and sedative properties.

Related product monographs

Title Information Source Document Type  
ATARAX Film-coated tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Canada (CA)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Japan (JP)

Malta (MT)

Mexico (MX)

Poland (PL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.